Nation-wide registry for chronic hepatitis C patients in Taiwan
Official title: Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan
Run by Kaohsiung Medical University Chung-Ho Memorial Hospital · NCT03200379 · Data updated 2026-11-12
This study is creating a nationwide database to see how well new hepatitis C treatments work and how safe they are for patients in Taiwan.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 150000 (estimated) |
| Sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital Academic / other |
| Locations | 1 site (Kaohsiung City) |
| Status | Recruiting |
| Started | June 15, 2017 |
| Main results expected | June 15, 2037 |
| Study ends | June 15, 2037 |
| Registry record updated | April 8, 2022 |
| Trial ID | NCT03200379 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are chronic hepatitis C patients who are currently being treated with directly acting antivirals and are willing to participate.
✕Probably not a fit
Patients who are unwilling to participate or do not provide informed consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to establish a nationwide registry to evaluate the efficacy, safety, and long-term outcomes of chronic hepatitis C patients receiving directly acting antivirals (DAAs) in Taiwan. It will collect data from both academic and community practices to assess real-world effectiveness and identify clinical gaps in treatment guidelines and management of adverse events. The registry will be supported by the National Health Insurance Administration (NHIA) to ensure comprehensive data collection and analysis. By creating this database, the study seeks to provide valuable insights into the treatment of hepatitis C in the Taiwanese population.
Why it matters
Potential benefit: If successful, this registry could lead to improved treatment strategies and better health outcomes for chronic hepatitis C patients.
How similar studies have gone: Other studies have shown success with similar registry approaches in evaluating treatment outcomes for chronic diseases, indicating potential for valuable insights from this study.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1\. Patients who are treated with DAA and have willingness to participate in this registry. Exclusion Criteria: Chronic hepatitis C patients who are unwilling to participate in the study and do not provide written informed consent for participation.
Where it's running
-
HepatobiliaryDivision, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Kaohsiung City, Taiwan Recruiting
Study contacts
- Principal investigator: Ming-Lung Yu, MD., PhD — HepatobiliaryDivision, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
- Study coordinator: Ming-Lung Yu, MD., PhD
- Email: fish6069@gmail.com
- Phone: 88673121101
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Improving early diagnosis of liver cancer in high-risk patients in China
This study is testing if regular check-ups for liver cancer can help catch the disease earlier in people at high risk due to conditions like chronic hepatitis or cirrhosis in China.
-
Impact of functional cure on patient-reported outcomes in chronic hepatitis B
This study tests whether people with chronic hepatitis B who achieve a functional cure have better patient-reported outcomes compared to those not cured, relapse, or healthy controls.
-
Sequential combination therapy for functional cure of chronic hepatitis B
This trial tests a new two-drug approach to see if adding immunotherapy to ongoing HBV treatment can lead to loss of hepatitis B surface antigen in adults with chronic hepatitis B.
-
Combination therapy for functional cure in chronic hepatitis B
This phase 2 trial tests whether a sequence of anti-PD-1/PD-L1 antibodies with pegylated interferon and nucleos(t)ide analogues can achieve functional cure (HBsAg loss) in adults with chronic hepatitis B.
-
GST-HG131/GST-HG141 tablets vs placebo in chronic hepatitis B
A phase IIa trial tests GST-HG131 and GST-HG141 tablets against placebo to see if they are safe and help people with chronic hepatitis B.
-
AHB-137 injection in people with chronic hepatitis B
This study tests AHB-137 vs placebo in adults with chronic hepatitis B who have not yet received antiviral treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.